drugset / Trial / NCT03570476
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
Phase 2
Terminated
2 enrolled
University of Washington
AstraZeneca · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized). Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Timeline
- Start
- 2018-09-11
- Primary completion
- 2019-05-31
- Completion
- 2019-07-03
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | — | Oral |